|

Zanzalintinib Clinical Trials

15 actively recruiting trials across 9 locations

Also known as: Multi-kinase Inhibitor XL092, XL 092, XL-092, XL092

Pipeline

Phase 1: 5Phase 2: 6Phase 3: 1Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • Washington University School of Medicine4
  • Northwestern University2
  • Merck Sharp & Dohme LLC2
  • M.D. Anderson Cancer Center2
  • Exelixis2

Indications

  • Cancer15
  • Liver Disease2
  • Renal Cell Carcinoma2
  • Liver Cancer2
  • Advanced Liposarcoma1

Chicago, Illinois3 trials

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

University of Chicago Medicine Comprehensive Cancer Center

Phase 1
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

Northwestern University

Phase 2
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Northwestern University

Phase 2

San Francisco, California2 trials

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

UCSF Medical Center at Mission Bay ( Site 5008)

Phase 1/2
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

University of California, San Francisco

Phase 1

St Louis, Missouri2 trials

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Washington University School of Medicine

Phase 1
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 1

Houston, Texas2 trials

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

The University of Texas M. D. Anderson Cancer Center

Phase 2
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

MD Anderson Cancer Center

Phase 2

Other1 trial

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Phase 3

Birmingham, Alabama1 trial

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Exelixis Clinical Site #43

Phase 2/3

Phoenix, Arizona1 trial

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Exelixis Clinical Site #67

Phase 1

Indianapolis, Indiana1 trial

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Phase 1/2

Rochester, Minnesota1 trial

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

Mayo Clinic - Rochester

Phase 2

Pittsburgh, Pennsylvania1 trial

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

UPMC Hillman Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.